Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028336 | 0.84 | KCNH2 (0.47) | MCHR1KCNH2 | |
| SCHEMBL7034662 | 0.82 | KCNH2 (0.42) | KCNH2MMP2 | |
| SCHEMBL6987304 | 0.82 | MCHR1 (0.46) | MCHR1KCNH2MMP2ANPEP | |
| SCHEMBL7036599 | 0.80 | SIGMAR1 (0.43) | KCNH2MMP2 | |
| SCHEMBL7030390 | 0.80 | KCNH2 (0.43) | KCNH2MMP2POLB | |
| SCHEMBL7027091 | 0.79 | MCHR1 (0.49) | MCHR1KCNH2 | |
| SCHEMBL7030606 | 0.79 | KCNH2 (0.42) | KCNH2MMP2 | |
| SCHEMBL7033619 | 0.79 | KCNH2 (0.39) | KCNH2MMP2 | |
| SCHEMBL7034139 | 0.78 | EPHX2 (0.45) | KCNH2 | |
| SCHEMBL6742864 | 0.78 | KCNH2 (0.44) | MCHR1KCNH2POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | MCHR1 1346/4885KCNH2 7/4885MMP2 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.